Switching antipsychotic medications

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 63-72

  Weiden, Peter J ^a   Aquila, Ralph ^a   Dalheim, Laura ^a   Standard, Janet M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; RISPERIDONE; THIORIDAZINE;

AKATHISIA; ANXIETY; ARTICLE; DEPRESSION; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF ESTEEM; TARDIVE DYSKINESIA; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG ADMINISTRATION ROUTES; DRUG COSTS; FEMALE; HOSPITALIZATION; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PIRENZEPINE; SCHIZOPHRENIA;

EID: 0030763124     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Borison R. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clin Ther 1996;18:592-607
2. Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 1993;44:1155-1161
3. Weiden P. Using depot therapy. J Pract Psychiatry Behav Health 1995;1:247-250
4. Weiden P. Understanding depot therapy in schizophrenia. J Pract Psychiatry Behav Health 1995;1:182-184
5. Weiden P. Using atypical antipsychotics. J Pract Psychiatry Behav Health 1995;1:115-119
6. Yadalam KG, Simpson GM. Changing from oral to depot fluphenazine. J Clin Psychiatry 1988;49:346-348
7. Borison R. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychiatry 1995;15(suppl 1):24-29
8. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287
9. Essock S, Hargreaves WA, Dohm FA, et al. Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22:15-25
10. Satterlee W, Dellva M, Beasley C, et al. Effectiveness of olanzapine in long-term continuation treatment. Presented at the meeting of the NCDEU; June 2, 1996; Boca Raton, Fla
11. Breier A, Buchanan RW, Kirkpatrick B, et al. Clozapine treatment in schizophrenic outpatients: preliminary results from a double-blind efficacy study. Schizophr Res 1991;4:315-320
12. Owens D. Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs 1996;51:895-930
13. Street J, Tamura R, Sanger T, et al. A comparison of the incidence of treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the meeting of the NCDEU; June 2, 1996; Boca Raton, Fla
14. Lieberman J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
15. Kinon B, Lieberman J. Mechanism of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34
16. Kopelowicz A. And when they awaken what will they find? J Calif Alliance Mentally Ill 1996;7:15-16
17. Wingerson D. Awakenings - to what? J Calif Alliance Mentally Ill 1996;7: 12-14
18. Bentley V. My life on Risperdal: coming out of the fog and into all sorts of unexpected. J Calif Alliance Mentally Ill 1996;7:49-51
19. Baldessarini R. Drugs in the treatment of psychiatric disorders: psychosis and anxiety. In: Molinoff P, Ruddon R, eds. Goodman & Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw-Hill; 1996: 399-430
20. Post L. Gaining clarity: unwanted awakenings. J Calif Alliance Mentally Ill 1996;7:21-22
21. Larsen P, Ashleigh E. Response to risperidone: a two edged sword? J Calif Alliance Mentally Ill 1996;7:17-18
22. Shiovitz T, Welke T, Tigel P, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22: 591-595
23. Baldessarini R, Gardner D, Garver D. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1996;52:1071-1072
24. Still D, Dorson P, Crimson M, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-1384
25. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21:333-337
26. de Leon J, Stanilla J, White A, et al. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994;55:119-120
27. de Leon J, Canuso C, White A, et al. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Community Psychiatry 1994;45:606-607
28. Gilbert P, Harris J, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173-188
29. Gardos G, Cole J, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135:1321-1324
30. Dilsaver S, Alessi N. Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand 1988;77:241-246
31. Luchins D, Freed W, Wyatt R. The role of cholinergic supersensitivity in the medical symptoms associated with the withdrawal of antipsychotic drugs. Am J Psychiatry 1980;137:1395-1398
32. Verghese C, DeLeon J, Nair C, et al. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996; 39:135-138
33. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994;10:103-114
34. Baker L, Cheng L, Amara I. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983;143:584-590
35. Gardos G, Cole J, Rapkin R, et al. Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry 1984;41:1030-1035
36. Manos N, Gkiouzepas J, Tzotzoras T, et al. Gradual withdrawal of antiparkinsonian medication in chronic schizophrenics: any better than abrupt? J Nerv Ment Dis 1981;169:659-661
37. Jellinek T, Gardos G, Cole J. Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 1981;138:1567-1571
38. Perenyi A, Gardos G, Samu I, et al. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal. Clin Neuropharmacol 1983;6: 55-61
39. Simpson G, Kunz-Bartholini E. Relationship of tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst 1968;29:269-274
40. Simpson G, Amin M, Kunz E. Withdrawal effects of phenothiazines. Compr Psychiatry 1965;29:269-274
41. Radford J, Brown T, Borison R. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995;15:225-226
42. Caroli F, Littre-Poirrier MF, Ginestet D, et al. Essai d'interruption des antiparkinsoniens dans les traitments neuroleptiques au long cours. L'Encephale 1975;1:69-74
43. Hershon H, Kennedy P, McGuire R. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 1972;120:41-50
44. Manos N, Gkiouzepas J, Logothetis I. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981;138:184-188
45. Rivera UM, Keichian AH, Oliver RE. Persistent parkinsonism following neuroleptanalgesia. Anesthesiology 1976;42:635-637
46. Birket-Smith E. Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand 1974;50:801-811
47. Branchey MH, Branchey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia. Psychopharmacol Bull 1981;17:118-119
48. Carpenter W, Rey A, Stephens J. Covert dyskinesia in ambulatory schizophrenics. Lancet 1979;2:506
49. Dixon L, Thaker G, Conley R, et al. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res 1993;10:267-271
50. Escobar J, Tuason V. Neuroleptic withdrawal dyskinesia. Psychol Bull 1979;15:71-74
51. Perenyi A, Frecska E, Bagdy G, et al. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment. Acta Psychiatr Scand 1985;72:430-435
52. Songer DA, Schulte HM. Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. J Clin Psychiatry 1996;57:40
53. Wirshing WC, Freidenberg DL, Cummings JL, et al. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol 1989;9:407-411
54. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57:53-60
55. Beasley C, Tran P, Tamura R, et al. Olanzapine versus haloperidol: results of the multicenter international trial. Presented at the 34th annual meeting of the ACNP; December 1995; San Juan, Puerto Rico
56. Moore N, Tupper D, Hotten T. Olanzapine. Drugs of the Future 1994;19: 114-117
57. Beasley C, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124:159-167
58. Casey D. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57:40-45
59. Conley R, Tamminga C, Group MS. Olanzapine vs chlorpromazine in treatment-resistant schizophrenia. Presented at the 37th annual meeting of the New Clinical Drug Evaluation Unit; 1997; Boca Raton, Fla
60. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796